Aadi Bioscience, Inc. (AADI)
|52 Week Range||11.0-21.15|
|1y Target Est||-|
|DCF Unlevered||AADI DCF ->|
|DCF Levered||AADI LDCF ->|
|Debt / Equity||14.78%||Neutral|
Upgrades & Downgrades
Latest AADI news
Aadi Bioscience, Inc. (AADI) Upgraded to Buy: What Does It Mean for the Stock?
6 January 2023
Aadi Bioscience, Inc. (AADI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aadi Bioscience, Inc. (AADI) Q3 2022 Earnings Call Transcript
9 November 2022
Aadi Bioscience, Inc. (NASDAQ:AADI ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Marcy Graham - Senior Vice President of Investor Relations & Corporate Communicat...
Aadi Bioscience: Taking mTOR Inhibition To The Next Level
21 September 2022
Shares have lost half their value since reverse merger with Aerpio Pharmaceuticals. Aadi aims to deliver on the broad potential of mTOR inhibition via nab technology to achieve wide therapeutic index ...
Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q2 2022 Results - Earnings Call Transcript
10 August 2022
Aadi Bioscience, Inc. (NASDAQ:AADI ) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Marcy Graham - SVP of IR and Corporate Communications Neil Desai - President and C...
Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
18 May 2022
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined ca...
Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q1 2022 Results - Earnings Call Transcript
12 May 2022
Aadi Bioscience, Inc. (NASDAQ:AADI ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Andrew Quan - VP, Business Development & Corporate Strategy Neil Desai - Founder, Pre...
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
28 April 2022
Company to hold conference call on May 12th at 8:30 am EDT Company to hold conference call on May 12th at 8:30 am EDT
Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
4 January 2022
LOS ANGELES, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR path...
Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning
25 November 2021
Aadi Bioscience receives FDA approval of Fyarro for treatment of patients with PEComa. Fyarro (ABI-009) can be expanded upon in two specific gene pathways known as TSC1 and TSC2; this could bring acce...